Novartis joins the growing trend of 'Big Pharma' exiting antibiotics drug development - dumping research, cutting 140 staffers and out-licensing programs.

Novartis joins the growing trend of 'Big Pharma' exiting antibiotics drug development - dumping research, cutting 140 staffers and out-licensing programs.: https://ift.tt/2u9sv4j Read more... https://ift.tt/2Nao4Ns